Angiogenesis is a fundamental process in various physiologic and pathologic processes. The ability to visualize and quantify angiogenesis will allow early diagnosis and monitoring for clinical determination of angiogenesis states before, during, and after adjuvant antiangiogenic and therapeutic angiogenesis treatments.
In recent years, angiogenesis has become one of the most important and intensely studied areas of cancer research, with the future holding great promise. Angiogenesis is a fundamental process in various physiologic and pathologic processes. The ability to visualize and quantify angiogenesis will allow early diagnosis and monitoring for clinical determination of angiogenesis states before, during, and after adjuvant antiangiogenic and therapeutic angiogenesis treatments. Investigators have identified more than 20 angiogenic growth factors, their receptors, and the details of their signal transduction pathways. Achievements with the vascular endothelial growth factor (VEGF) antibody bevacizumab (Avastin; Genentech) in combination with standard cytotoxic chemotherapy in metastasized colorectal cancer, breast cancer, and non-small cell lung cancer (1) are among them. However, although new antiangiogenic therapies are continually being introduced into clinical trials, we believe that the future success of these therapies will require the codevelopment of high-throughput, cost-effective imaging techniques with highly specific biomarkers of angiogenesis to determine optimal doses and individual response to therapy on a structural, functional, and molecular level. In the future, we believe that angiogenesis imaging will serve as an early diagnostic and monitoring tool for the clinical determination of angiogenesis states before, during, and after adjuvant antiangiogenic cancer therapy.
STRUCTURAL IMAGING OF ANGIOGENESIS
Several research and clinical imaging modalities are available for visualizing the structure of microvasculature such as intravital microscopy, CT angiography, contrast-enhanced ultrasound, and high-resolution magnetic resonance angiography. Multidetector CT angiography allows for larger scan volumes in less time with improved spatial and temporal resolution, making it possible to image different vascular phases using the same contrast bolus to compare the vasculature of tumors with that of normal organs. In addition, CT angiography provides a quick, noninvasive, low-dose alternative to conventional digital subtraction angiography in a research setting, and CT angiography has the potential to provide invaluable information about surrounding nonvascular structures and both arterial and venous systems. However, the spatial resolution of MDCT is still not enough for microvasculature visualization (2) . To improve the number of photons produced per unit-area per second of benchtop x-ray sources, radiation micro-CT using synchrotron light has been applied for improved spatial and contrast resolution. Several cubic millimeters of microvasculature including capillaries can be visualized with a combination of pure absorption and edge enhancement at a voxel size of 1.4 mm (3).
Micro-CT is a promising method to visualize the vascular architecture of normal organs and tumors and to derive quantitative imaging information. However, the long scan periods and high x-ray doses of micro-CT make it unsuitable for repeated noninvasive vessel measurements. Kiessling et al. reported a prototype volumetric CT apparatus for high-resolution imaging in experimental and preclinical applications in vivo that combines the advantages of micro-CT and clinical CT scanners (4) . Reconstructed volumetric CT images have a high resolution, with isotropic voxels of less than 4 · 10 24 mm 3 , and the minimum vessel diameter visualized by volumetric CT varies between 40 and 50 mm (Fig. 1) . Advances with volumetric CT help fill the gap between clinical multislice CT and preclinical micro-CT systems and is highly suited for studying orthotopic and metastasizing tumor models.
FUNCTIONAL IMAGING OF ANGIOGENESIS
Dynamic contrast-enhanced MRI is a noninvasive method of imaging microvascular structure by tracking the pharmacokinetics of an injected contrast agent as it passes through tumor vasculature. This technique measures changes in vascular permeability, extravascular and vascular volumes, and blood flow. Dynamic contrastenhanced MRI has been used for evaluation of drug efficacy in several trials of antiangiogenic drugs. Overall, dynamic contrastenhanced MRI is promising as an imaging biomarker in clinical trials. However, data on its performance, especially for response assessment, are not uniform and seem to depend strongly on the therapy protocol and tumor type.
The simplicity, ease of use, speed, and safety of ultrasound for angiogenesis imaging has led to its increased use in disease diagnosis, treatment assessment, follow-up, and therapy guidance. Ultrasound can be applied to image the microcirculation using both Doppler and microbubble techniques. Power Doppler can be quantified to give an estimate of relative fractional vascular volume and blood velocity. Innovations in the field of ultrasound imaging have made it possible to measure blood-flow microvasculature of less than 100 mm. At frequencies on the order of 50 MHz, Doppler processing allows for the direct assessment of flow dynamics in real time in arterioles as small as 15 mm (5). Ultrasound using microbubbles can show blood flow down to the microcirculation level by raising the signal emitted from smaller vessels. However, microbubbles are limited by their relatively larger size (1-10 mm in diameter). This increased size in comparison with smaller contrast agents provides access to the bulk properties of the microvascular compartment but does not provide sufficient resolution to allow observation of microvasculature morphology and detailed flow characteristics.
Optical imaging is a low-cost method that offers single-cell resolution and real-time imaging to monitor tumor-host interactions-a component critical to tumor development and angiogenesis. Optical imaging has the ability to determine tumor vascular permeability, vessel size, and blood flow in vivo and can offer great clarity for imaging blood vessels using fluorescent dyes or quantum dots. Several high-resolution microscopic optical imaging techniques have recently been developed to study molecular events in vivo such as intravital fluorescence microscopy, confocal laser scanning microscopy, multiphoton laser scanning microscopy, and in situ scanning force microscopy (6,7). The major limitation of optical imaging is tissue light scattering and absorption, which affect both image resolution and the depth of light penetration in tissues.
MOLECULAR IMAGING
Although imaging techniques such as dynamic contrast-enhanced MRI are widely used to assess hemodynamic parameters, the physiologic meaning of results from these studies often remains difficult to interpret. Therefore, more specific markers of tumor angiogenic activity are necessary for pretherapeutic angiogenesis assessment and posttherapy response evaluation. Molecules regulating angiogenesis include, but are not limited to, growth factor receptors, tyrosine kinase receptors, G-protein-coupled receptors for angiogenesis modulating proteins, integrins, and matrix metalloproteinases. Here, we will focus on 2 of the most intensively studied angiogenesis-related molecular targets: integrin a v b 3 and VEGF receptors (VEGFRs).
Integrins are a family of cell adhesion molecules playing key roles during tumor angiogenesis and metastasis (8, 9) . Integrins expressed on endothelial cells modulate cell migration and survival during tumor angiogenesis, whereas integrins expressed on carcinoma cells potentiate metastasis by facilitating invasion and movement across blood vessels. The a v b 3 integrin, which binds to arginine-glycineaspartic acid (RGD)-containing components of the extracellular matrix, is significantly upregulated on tumor vasculature but not on quiescent endothelium (9, 10) . Several comprehensive reviews on multimodality imaging of integrin expression (PET, SPECT, MRI, ultrasound, and optical) using appropriate cyclic RGD peptides and monoclonal antibodies against integrin a v b 3 have been published (11) (12) (13) (14) (15) (16) . Among these, PETof integrin a v b 3 using the radiotracer 18 Fgalacto-RGD has been tested in humans with good contrast and with a low radiation dose, comparable to that of 18 F-FDG (Fig. 2) (17-20) . It has also been shown that the intensity of 18 F-galacto-RGD uptake correlates with a v b 3 expression in murine tumor xenografts and in patients with cancer. The same tracer is now being evaluated for clinical use in different tumor entities.
Most monomeric RGD peptide-based tracers tend to have fast blood clearance accompanied by relatively low tumor uptake and rapid tumor washout, presumably because of the suboptimal receptor-binding affinity/selectivity and inadequate contact with Multimerization of cyclic RGD peptides has been repeatedly demonstrated to increase integrin affinity and enhance antiadhesion ability against integrin a v b 3 and thus significantly improve tumor targeting over the monomeric RGD analogs (11, 12, (21) (22) (23) (24) (25) (26) . The polyvalency effect has been most beneficial in tumors with low to medium integrin expression (26) . Several dimeric and multimeric RGD peptide-based imaging probes are in the process of clinical translation for the first studies on humans. Whether such new probes will have advantages over 18 F-galacto-RGD remains to be elucidated.
Integrin a v b 3 is not an angiogenesis marker per se because of its nonexclusive expression on the neovasculature. Small molecules, even antibody-based probes for integrin expression, do not provide an accurate readout of tumor angiogenesis because these probes bind to integrin a v b 3 expressed on both the tumor vasculature and tumor cells. Because of their relatively large sizes and rigid structure, integrin-targeted nanoparticles that do not extravasate are probably true vascular integrin-specific probes (27, 28) . A few such examples include RGD peptide-coupled quantum dots for near-infrared fluorescence imaging, single-walled nanotubes for Raman and photoacoustic imaging, liposomal and perfluorocarbon nanoparticles for T1-weighted MRI, ultrasmall superparamagnetic iron oxide particles for T2-weighted MRI, and microbubbles for contrast-enhanced ultrasound. Several of these nanoparticle conjugates have also been suitably labeled for radionuclide imaging to assess the tumortargeting efficacy and in vivo kinetics of the particles in a more quantitative manner.
The angiogenic actions of VEGF are mediated mainly via 2 endothelium-specific receptor tyrosine kinase receptors, Flt-1 (VEGFR-1) and Flk-1/KDR (VEGFR-2). Both VEGFRs are restricted largely to vascular endothelial cells, and all VEGF-A isoforms bind to both VEGFR-1 and VEGFR-2. It is now generally accepted that VEGFR-2 is the major mediator of the mitogenic, angiogenic, and permeability-enhancing effects of VEGF. The critical role of VEGF-A in cancer progression has been highlighted by the approval of the humanized anti-VEGF monoclonal antibody bevacizumab (Avastin; Genentech) for first-line treatment (29) . The flourishing investigations of both radionuclide-and non-radionuclidebased VEGFR imaging studies stem from the successful initial clinical evaluation of 123 I-VEGF 165 in patients with gastrointestinal cancer (30, 31) . Development of VEGF-or VEGFR-targeted molecular imaging probes is a potential new paradigm for assessing antiangiogenic therapies and clarifying the role and expression profile of VEGF/VEGFR in angiogenesis-related diseases (32) .
Imaging probes based on wild-type VEGF-A isoforms bind to both VEGFR-1 and VEGFR-2. The kidneys have high VEGFR-1 expression that can take up VEGF-A-based tracer and thus usually makes the kidney the dose-limiting organ (33, 34) . Because VEGFR-2 is generally accepted to be more functionally important than VEGFR-1 in cancer progression, the ability to image VEGFR-2 expression can be a valuable tool for evaluating patients with a variety of malignancies, particularly those undergoing anti-VEGFR-2 therapies. Alanine-scanning mutagenesis has been used to identify a positively charged surface in VEGF 165 that mediates binding to VEGFR-2 (35) . Arg 82 , Lys 84 , and His 86 , located in a hairpin loop, were found to be critical for binding VEGFR-2, whereas negatively charged residues, Asp 63 , Glu 64 , and Glu 67 , were associated with VEGFR-1 binding. A VEGFR-2-specific PET tracer has thus been developed using the D63AE64AE67A mutant of VEGF 121 (VEGF DEE ) generated by recombinant DNA technology. Renal uptake of 64 Cu-tetraazacyclododecanetetraacetic acid (DOTA)-VEGF DEE was significantly lower than that of 64 Cu-DOTA-VEGF 121 (Fig. 3) (36) . Further improvement in VEGFR-2 binding affinity/specificity, pharmacokinetics, and tumor-targeting efficacy by generation of other VEGF 121 mutants is considered a good direction for clinical translation of VEGF protein-based imaging probes.
FUTURE PERSPECTIVES
Numerous imaging techniques are now available to visualize tissue vasculature on a structural, functional, and molecular level. All these techniques have undergone significant preclinical development in (Reprinted with permission of (36) .) recent years and should aid in future assessment of angiogenesis, monitoring of antiangiogenic treatment, and antiangiogenic drug development. Only vascular imaging of functional hemodynamic parameters such as K trans , blood flow, and blood volume are currently being used clinically to assess antiangiogenic and cytotoxic chemotherapies. However, the physiologic meaning of these results is often difficult to interpret.
With molecular imaging of angiogenesis, only a few radiotracers have been used in humans thus far, and the role of these tracers in assessing response to antiangiogenic therapies is still undetermined. Although integrin a v b 3 is by far the most extensively studied angiogenic factor for imaging, future trials still need to elucidate which target structure is optimal for assessing angiogenesis. In regard to which imaging technique is optimal, the radiotracer approach will likely be the first to be used on a wider scale in patients in the intermediate term because of its high sensitivity and the low amounts of tracer required. However, over the long term, MRI might be a better imaging alternative because of its lack of ionizing radiation and high spatial resolution. Overall, it is likely that angiogenesis will eventually be assessed not using a single parameter, target structure, or imaging technique but rather a combination of parameters that allow for a multimodal imaging evaluation of the intricacies of the angiogenic cascade. Assessing the different aspects of angiogenesis
